Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Belinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 19/20 | 1.00 |
| ▸ | HDAC3 known ✓ | O15379 | 17/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 17/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 17/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 17/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 17/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 17/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 17/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 17/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 17/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Belinostat SCHEMBL29712104 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| Belinostat SCHEMBL375656 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| Belinostat SCHEMBL29379950 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL1403368 | 0.93 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL1403370 | 0.93 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL1403252 | 0.92 | HDAC8 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL1403249 | 0.92 | HDAC8 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL13762589 | 0.90 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL12808803 | 0.90 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL13762584 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8324 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-12637498-B2 | PDLIM2 as a biomarker for cancer and as an anti-cancer treatment target | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026102034-A1 | COMPOSITIONS AND METHODS FOR GENETIC AND EPIGENETIC MODULATION | JUNIPERO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| CN-122029214-A | Phospholipid drug conjugate and preparation method and application thereof | 上海弼领生物技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260125428-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | UNIV CONNECTICUT (US) | 2026-05-07 | — | — | US | claimed |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | SPECTRUM PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20110003777-A1 | Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat | TOPOTARGET A/S (DK) | 2011-01-06 | — | — | US | claimed |
| EP-2262493-A1 | METHODS OF TREATMENT EMPLOYING PROLONGED CONTINUOUS INFUSION OF BELINOSTAT | Topotarget A/S (DK) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109861-A1 | METHODS OF TREATMENT EMPLOYING PROLONGED CONTINUOUS INFUSION OF BELINOSTAT | TOPOTARGET A/S (DK) | 2009-09-11 | — | — | WO | claimed |
| WO-2008090534-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EXCESSIVE WEIGHT GAIN, REDUCTION OF INAPPROPRIATE EATING BEHAVIOURS AND INHIBITION OF BINGE EATING FOR THE TREATMENT OF OBESITY | BERAND LIMITED (IE) | 2008-07-31 | — | — | WO | claimed |
| US-20080119424-A1 | Combined Use of Prame Inhibitors and Hdac Inhibitors | BERNARDS RENE | 2008-05-22 | — | — | US | claimed |
| WO-2007049262-A1 | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders | BERAND LIMITED (IE) | 2007-05-03 | — | — | WO | claimed |
| EP-1711210-A2 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | Vereniging Het Nederlands Kanker Instituut (NL) | 2006-10-18 | — | — | EP | claimed |
| WO-2005074995-A2 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | VERENIGING HET NEDERLANDS KANKER INSTITUUT (NL) | 2005-08-18 | — | — | WO | claimed |